Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Roche Issues Two Milestone Payments

  • Memory Pharmaceuticals received a $2-million milestone from Roche related to MEM 3454. This is Memory’s lead compound for the treatment of neurological and psychiatric disorders. It is a result of the companies' alliance focused on the discovery and clinical development of nicotinic alpha-7 receptor agonists. Roche also elected to maintain its option to obtain an exclusive license for MEM 3454.

    Separately, Amira Pharmaceuticals received its first milestone payment from Roche nine months after the start of their research collaboration. The payment is the result of a collaboration in the field of inflammatory disease. Amira has identified a series of drug candidates against one mutually agreed target.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »